Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360637 | 0.90 | SMN1; SMN2 (0.41) | MAPTMEN1KMT2AABL1TSHR | |
| SCHEMBL1361748 | 0.89 | NR1I3 (0.42) | MAPTNR1I3 | |
| SCHEMBL12138920 | 0.89 | SCD (0.39) | MAPTNR1I3TP53 | |
| SCHEMBL1360955 | 0.87 | NR1I3 (0.35) | MAPTNR1I3TP53 | |
| SCHEMBL12140418 | 0.84 | MAPT (0.41) | MAPTMEN1KMT2AL3MBTL1CRHBP | |
| SCHEMBL1359897 | 0.82 | MAPT (0.42) | MAPTMEN1KMT2AL3MBTL1CRHBP | |
| SCHEMBL1151099 | 0.81 | CRHBP (0.40) | MAPTMEN1KMT2AL3MBTL1CRHBP | |
| SCHEMBL1220959 | 0.75 | SLC2A1 (0.50) | MAPTTSHRALOX5TP53 | |
| SCHEMBL12140788 | 0.74 | POLB (0.37) | MAPTMEN1KMT2AABL1TP53 | |
| SCHEMBL1359882 | 0.74 | ALDH1A1 (0.37) | MEN1KMT2AABL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| EP-2247601-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010000030-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000030-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | TPMT, CYP2C19, CYP3A5 | MAPT 2414/4885MEN1 1438/4885KMT2A 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.